MiR-940 inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients

Cancer Science

Volumn 106, Issue 7, 2015, Pages 819-824

  Yuan, Bo ^a   Liang, Yasha ^a   Wang, Duoning ^a   Luo, Fengming ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cell proliferation; Estrogen related receptor gamma; Hepatocellular carcinoma; MiR 940; Patients' survival

Indexed keywords

ESTROGEN RELATED RECEPTOR GAMMA; MESSENGER RNA; MICRORNA; MICRORNA 940; STEROID RECEPTOR; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ESRRG PROTEIN, HUMAN; ESTROGEN RECEPTOR; MIRN940 MICRORNA, HUMAN;

ALGORITHM; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; SURVIVAL RATE; SURVIVAL TIME; WESTERN BLOTTING; 3' UNTRANSLATED REGION; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; RNA INTERFERENCE;

3' UNTRANSLATED REGIONS; APOPTOSIS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MICRORNAS; PROGNOSIS; RECEPTORS, ESTROGEN; RNA INTERFERENCE;

EID: 84936985613     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12688     Document Type: Article

References (38)

1. El-Serag HB. Hepatocellular carcinoma. N Eng J Med 2011; 365: 1118-27.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
4. Hou J, Zhou Y, Zheng Y et al. Hepatic RIG-I predicts survival and interferon-alpha therapeutic response in hepatocellular carcinoma. Cancer Cell 2014; 25: 49-63.
5. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
6. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001; 107: 823-6.
7. Gramantieri L, Ferracin M, Fornari F et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-9.
8. Budhu A, Jia HL, Forgues M et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008; 47: 897-907.
9. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009; 50: 113-21.
10. Su H, Yang JR, Xu T et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69: 1135-42.
11. Murakami Y, Yasuda T, Saigo K et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537-45.
12. Braconi C, Patel T. MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumors. Hepatology 2008; 47: 1807-9.
13. Murakami Y, Tamori A, Itami S et al. The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer 2013; 13: 99.
14. Gramantieri L, Fornari F, Callegari E et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 2008; 12: 2189-204.
15. Wang B, Majumder S, Nuovo G et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009; 50: 1152-61.
16. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28: 3526-36.
17. Ji J, Shi J, Budhu A et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Eng J Med 2009; 361: 1437-47.
18. Ji J, Yamashita T, Budhu A et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009; 50: 472-80.
19. Ladeiro Y, Couchy G, Balabaud C et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 47: 1955-63.
20. Song G, Sharma AD, Roll GR et al. MicroRNAs control hepatocyte proliferation during liver regeneration. Hepatology 2010; 51: 1735-43.
21. Ura S, Honda M, Yamashita T et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009; 49: 1098-112.
22. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008; 14: 2588-92.
23. Wang Y, Lee AT, Ma JZ et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008; 283: 13205-15.
24. Ma J, Sun F, Li C et al. Depletion of intermediate filament protein Nestin, a target of microRNA-940, suppresses tumorigenesis by inducing spontaneous DNA damage accumulation in human nasopharyngeal carcinoma. Cell Deat Dis 2014; 5: e1377.
25. Rajendiran S, Parwani AV, Hare RJ, Dasgupta S, Roby RK, Vishwanatha JK. MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1. Mol Cancer 2014; 13: 250.
26. van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol 2011; 731: 237-45.
27. Liu C, Zhou C, Gao F et al. MiR-34a in age and tissue related radio-sensitivity and serum miR-34a as a novel indicator of radiation injury. Int J Biol Sci 2011; 7: 221-33.
28. Han ZB, Yang Z, Chi Y et al. MicroRNA-124 suppresses breast cancer cell growth and motility by targeting CD151. Cell Physiol Biochem 2013; 31: 823-32.
29. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
30. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
31. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007; 27: 91-105.
32. Garcia DM, Baek D, Shin C, Bell GW, Grimson A, Bartel DP. Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol 2011; 18: 1139-46.
33. Grentzmann G, Ingram JA, Kelly PJ, Gesteland RF, Atkins JF. A dual-luciferase reporter system for studying recoding signals. RNA 1998; 4: 479-86.
34. Zhao Q, Li T, Qi J, Liu J, Qin C. The miR-545/374a cluster encoded in the Ftx lncRNA is overexpressed in HBV-related hepatocellular carcinoma and promotes tumorigenesis and tumor progression. PLoS ONE 2014; 9: e109782.
35. Hou J, Lin L, Zhou W et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19: 232-43.
36. Li D, Liu X, Lin L et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 2011; 286: 36677-85.
37. Li CL, Yeh KH, Liu WH et al. Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor-alpha in female hepatocellular carcinoma. Int J Cancer 2015; 136: 761-70.
38. Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000; 10: 211-31.